| pubmed-article:10669364 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0027361 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0205466 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:10669364 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:10669364 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10669364 | pubmed:dateCreated | 2000-4-13 | lld:pubmed |
| pubmed-article:10669364 | pubmed:abstractText | The baseline predictors of poor virologic response (<0.5 log decrease in plasma virus load) were examined in two 1996 pilot trials of combination nucleoside-analogue therapy. One trial examined the addition of hydroxyurea to didanosine therapy; the other examined stavudine-lamivudine in combination. In both, predictors of virologic response included the presence of mutations associated with zidovudine resistance. For hydroxyurea, the odds ratio (OR) of failure to achieve a short-term (4 weeks) virologic response in a bivariate logistic regression model was 30.8 (95% confidence interval [CI], 1.75-543; P=.02) for use of lower dose hydroxyurea (500 mg/day) and 14.7 (95% CI, 1.1-200; P=.04) for the presence of a zidovudine-related mutation. For the stavudine-lamivudine study, the OR of failure to achieve a virologic response at 4 weeks in a multivariate logistic regression model was 23 (95% CI, 2.7-199; P=.004) for the presence of a mutation at codon 215. | lld:pubmed |
| pubmed-article:10669364 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10669364 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10669364 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10669364 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10669364 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:AlexanderC... | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:RouleauDD | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:RaeSS | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:ZalaCC | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:MoTT | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:MontanerJ SJS | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:HarriganP RPR | lld:pubmed |
| pubmed-article:10669364 | pubmed:author | pubmed-author:RaboudJ MJM | lld:pubmed |
| pubmed-article:10669364 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10669364 | pubmed:volume | 181 | lld:pubmed |
| pubmed-article:10669364 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10669364 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10669364 | pubmed:pagination | 729-32 | lld:pubmed |
| pubmed-article:10669364 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:meshHeading | pubmed-meshheading:10669364... | lld:pubmed |
| pubmed-article:10669364 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10669364 | pubmed:articleTitle | Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. | lld:pubmed |
| pubmed-article:10669364 | pubmed:affiliation | BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada V6Z 1Y6. | lld:pubmed |
| pubmed-article:10669364 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10669364 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10669364 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10669364 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10669364 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10669364 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10669364 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10669364 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10669364 | lld:pubmed |
